

Bart Neyns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7496017/publications.pdf>

Version: 2024-02-01

265
papers

24,371
citations

26630

56
h-index

7950

149
g-index

269
all docs

269
docs citations

269
times ranked

25153
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	27.0	4,838
2	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 375-384.	10.7	2,353
3	Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1658-1664.	1.6	1,828
4	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	1.6	1,525
5	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. <i>Lancet Oncology</i> , The, 2010, 11, 155-164.	10.7	1,075
6	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	13.7	1,032
7	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	10.7	812
8	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3212-3218.	1.6	489
9	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	1.6	458
10	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	1.6	431
11	Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2712-2718.	1.6	389
12	Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. <i>Nature Neuroscience</i> , 2021, 24, 595-610.	14.8	288
13	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-170.	1.6	283
14	Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1330-1338.	1.6	259
15	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444.	10.7	242
16	Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. <i>Annals of Oncology</i> , 2009, 20, 1596-1603.	1.2	207
17	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4431-4439.	3.6	187
18	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161.	1.2	170

#	ARTICLE	IF	CITATIONS
19	Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. <i>Annals of Oncology</i> , 2011, 22, 991-993.	1.2	167
20	Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA. <i>Molecular Therapy</i> , 2008, 16, 1170-1180.	8.2	166
21	A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. <i>Annals of Oncology</i> , 2013, 24, 2686-2693.	1.2	158
22	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. <i>European Journal of Endocrinology</i> , 2019, 181, 363-374.	3.7	154
23	Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. <i>ELife</i> , 2020, 9, .	6.0	154
24	Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. <i>Annals of Oncology</i> , 2013, 24, 2174-2180.	1.2	150
25	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1513-1537.	4.2	149
26	Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 3366-3375.	7.0	149
27	An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. <i>Annals of Oncology</i> , 2008, 19, 92-98.	1.2	147
28	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2017, 18, 464-472.	10.7	139
29	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	1.2	132
30	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
31	Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2011, 34, 448-456.	2.4	124
32	Phase II study of sunitinib malate in patients with recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 491-501.	2.9	119
33	Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. <i>Annals of Oncology</i> , 2014, 25, 2277-2284.	1.2	119
34	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. <i>Journal of Translational Medicine</i> , 2016, 14, 95.	4.4	117
35	Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. <i>World Neurosurgery</i> , 2009, 72, 423-428.	1.3	115
36	Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. <i>Melanoma Research</i> , 2012, 22, 466-472.	1.2	112

#	ARTICLE	IF	CITATIONS
37	A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. <i>BMC Cancer</i> , 2006, 6, 285.	2.6	103
38	Cilengitide: an RGD pentapeptide α 2 β 3 and α 5 β 1 integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , 2011, 7, 339-354.	2.4	98
39	Characterization of the <i>in vivo</i> immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. <i>Oncolmmunology</i> , 2015, 4, e982382.	4.6	95
40	TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. , 2020, 8, e000329.		93
41	Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. <i>European Journal of Cancer</i> , 2012, 48, 2004-2011.	2.8	92
42	Therapeutic depletion of CCR8 ⁺ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. , 2021, 9, e001749.		91
43	Dose-dense temozolomide regimens. <i>Cancer</i> , 2010, 116, 2868-2877.	4.1	89
44	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	4.4	89
45	Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells. <i>Journal of Immunology</i> , 2008, 180, 3585-3593.	0.8	86
46	Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients. <i>Molecular Therapy</i> , 2012, 20, 1063-1074.	8.2	85
47	Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. <i>Annals of Oncology</i> , 2022, 33, 1052-1060.	1.2	81
48	Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2013, 36, 215-222.	2.4	78
49	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. <i>Annals of Oncology</i> , 2021, 32, 917-925.	1.2	76
50	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 959-967.	4.2	74
51	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9503-9503.	1.6	71
52	Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 381-388.	4.2	70
53	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	1.2	69
54	Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. <i>Oncolmmunology</i> , 2015, 4, e998107.	4.6	65

#	ARTICLE	IF	CITATIONS
55	Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. <i>Anticancer Research</i> , 2012, 32, 1355-9.	1.1	65
56	Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. <i>Journal of Gene Medicine</i> , 2004, 6, 1175-1188.	2.8	63
57	Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1033-1043.	4.2	63
58	Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?. <i>British Journal of Dermatology</i> , 2014, 171, 987-995.	1.5	63
59	Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2018, 29, viii714.	1.2	60
60	Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2008, 62, 55-61.	2.0	59
61	Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. <i>BMC Cancer</i> , 2008, 8, 3.	2.6	58
62	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. <i>Oncolmmunology</i> , 2015, 4, e1019197.	4.6	55
63	Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2019, 2019, 1-17.	1.3	55
64	The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation. <i>Journal of Medical Genetics</i> , 2004, 41, 23e-23.	3.2	54
65	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 9.	4.4	54
66	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>Oncolmmunology</i> , 2022, 11, .	4.6	54
67	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9504-9504.	1.6	53
68	Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. <i>International Journal of Oncology</i> , 2012, 41, 1029-1035.	3.3	52
69	Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. <i>Journal of Neuro-Oncology</i> , 2014, 117, 141-145.	2.9	52
70	MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. <i>European Journal of Cancer</i> , 2009, 45, 146-153.	2.8	51
71	Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. <i>European Journal of Cancer</i> , 2012, 48, 3045-3051.	2.8	51
72	Tolerance of adjuvant letrozole outside of clinical trials. <i>Breast</i> , 2008, 17, 376-381.	2.2	49

#	ARTICLE	IF	CITATIONS
73	Vemurafenib-induced neutrophilic panniculitis. <i>Melanoma Research</i> , 2012, 22, 399-401.	1.2	46
74	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 828-835.	0.8	46
75	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , 2020, 20, 36.	2.8	46
76	Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. , 2021, 9, e002296.		45
77	Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. <i>Oncogene</i> , 1996, 12, 1247-57.	5.9	45
78	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2589-2598.	4.2	44
79	Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 147-155.	2.9	40
80	Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). <i>Journal of Clinical Oncology</i> , 2007, 25, 2000-2000.	1.6	40
81	A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma. <i>Cancer Investigation</i> , 2008, 26, 269-277.	1.3	39
82	Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. <i>Melanoma Research</i> , 2015, 25, 550-554.	1.2	39
83	Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 115-125.	2.9	39
84	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-554.	1.6	39
85	Characterization of CD8 ⁺ T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL). <i>BioMed Research International</i> , 2013, 2013, 1-8.	1.9	38
86	A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy. <i>Annals of Oncology</i> , 2014, 25, v1.	1.2	38
87	Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and ^{SP} 142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. <i>Histopathology</i> , 2017, 70, 253-263.	2.9	37
88	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. <i>European Journal of Cancer</i> , 2018, 104, 201-209.	2.8	37
89	Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?. <i>European Journal of Endocrinology</i> , 2021, 184, K1-K5.	3.7	37
90	Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-6.	0.3	35

#	ARTICLE	IF	CITATIONS
91	Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). , 2020, 8, e001146.		35
92	Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. American Journal of Cancer Research, 2016, 6, 2514-2531.	1.4	35
93	Temozolomide Dosing Regimens for Glioma Patients. Current Neurology and Neuroscience Reports, 2012, 12, 286-293.	4.2	34
94	Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study. Journal of Clinical Oncology, 2008, 26, 9025-9025.	1.6	34
95	Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. Cancer Immunology, Immunotherapy, 2016, 65, 727-740.	4.2	33
96	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. European Journal of Cancer, 2017, 75, 313-322.	2.8	32
97	Complete Cytologic Remission of V600E <i>BRAF</i>-Mutant Melanomaâ€Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib. Journal of Clinical Oncology, 2015, 33, e109-e111.	1.6	31
98	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 2017, 79, 176-184.	2.8	31
99	Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. Supportive Care in Cancer, 2020, 28, 3267-3278.	2.2	31
100	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. Journal of Clinical Oncology, 2019, 37, 635-635.	1.6	31
101	Non-Hodgkin's Lymphoma in Patients With Glioma Treated With Temozolomide. Journal of Clinical Oncology, 2008, 26, 4518-4519.	1.6	29
102	Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Annals of Hematology, 2008, 87, 495-496.	1.8	28
103	Primary leptomeningeal anaplastic oligodendroglioma with a 1p36â€19q13 deletion: Report of a unique case successfully treated with Temozolomide. Journal of the Neurological Sciences, 2009, 287, 267-270.	0.6	28
104	Pamidronate-Related Nephrotoxicity (Tubulointerstitial Nephritis) in a Patient with Osteolytic Bone Metastases. Nephron, 2001, 89, 467-468.	1.8	27
105	Phase II study of helical tomotherapy for oligometastatic colorectal cancer. Annals of Oncology, 2011, 22, 362-368.	1.2	27
106	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. Journal of Translational Medicine, 2016, 14, 232.	4.4	27
107	Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods. Archives of Pathology and Laboratory Medicine, 2018, 142, 982-991.	2.5	27
108	Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. Cancer Medicine, 2018, 7, 4870-4879.	2.8	27

#	ARTICLE	IF	CITATIONS
109	The role of cytotoxic drugs in the treatment of central nervous system gliomas. <i>Acta Neurologica Belgica</i> , 2010, 110, 1-14.	1.1	26
110	Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. <i>Anticancer Research</i> , 2011, 31, 4457-63.	1.1	26
111	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	3.0	25
112	Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. <i>Journal of Immunological Methods</i> , 2012, 377, 23-36.	1.4	24
113	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. <i>Cancers</i> , 2021, 13, 168.	3.7	24
114	Immunotherapy of Cancer with Dendritic Cells Loaded with Tumor Antigens and Activated Through mRNA Electroporation. <i>Methods in Molecular Biology</i> , 2010, 629, 403-450.	0.9	24
115	Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10013-10013.	1.6	23
116	Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2038-2038.	1.6	22
117	High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. <i>Journal of Medical Genetics</i> , 1999, 36, 304-8.	3.2	22
118	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. <i>ESMO Open</i> , 2019, 4, e000464.	4.5	21
119	Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. <i>Journal of Clinical Oncology</i> , 2009, 27, 9037-9037.	1.6	21
120	A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 753-759.	4.2	19
121	Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. <i>Blood Advances</i> , 2018, 2, 2156-2158.	5.2	19
122	Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. <i>Acta Oncologica</i> , 2021, 60, 69-77.	1.8	19
123	Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.. <i>Journal of Clinical Oncology</i> , 2021, 39, 58-58.	1.6	19
124	Loss of nuclear BRCA1 localization in breast carcinoma is age dependent. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 274-279.	2.8	18
125	Cetuximab Treatment in a Patient with Metastatic Colorectal Cancer and Psoriasis. <i>Current Oncology</i> , 2008, 15, 196-197.	2.2	18
126	Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. <i>Melanoma Research</i> , 2018, 28, 65-70.	1.2	18

#	ARTICLE	IF	CITATIONS
127	Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	2.2	18
128	Neuropathological and molecular aspects of low-grade and high-grade gliomas. <i>Acta Neurologica Belgica</i> , 2004, 104, 148-53.	1.1	18
129	Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 178-184.	4.2	17
130	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	4.4	17
131	The predictive and prognostic significance of cell-free DNA concentration in melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 387-395.	2.4	17
132	AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. <i>Oncotarget</i> , 2014, 5, 6801-6815.	1.8	17
133	Frequent deletion of chromosome 19 and a rare rearrangement of 19p13.3 involving the insulin receptor gene in human ovarian cancer. <i>Oncogene</i> , 1995, 11, 351-8.	5.9	17
134	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 157-163.	1.2	16
135	The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. <i>Clinical Lung Cancer</i> , 2021, 22, 432-440.	2.6	16
136	Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. <i>Anticancer Research</i> , 2006, 26, 611-9.	1.1	16
137	Alteration of Jun proto-oncogene status by plasmid transfection affects growth of human ovarian cancer cells. <i>Oncogene</i> , 1999, 82, 687-693.		15
138	18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancreatitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1390-1391.	6.4	15
139	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. <i>ESMO Open</i> , 2017, 2, e000203.	4.5	15
140	Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. <i>Melanoma Research</i> , 2019, 29, 85-88.	1.2	15
141	Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium. <i>Journal of Neuro-Oncology</i> , 2004, 70, 37-48.	2.9	14
142	Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. <i>European Journal of Cancer</i> , 2017, 72, S122-S123.	2.8	14
143	Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. <i>British Journal of Cancer</i> , 2001, 85, 1592-1599.	6.4	13
144	Techniques for the placement of hepatic artery catheters for regional chemotherapy in unresectable liver metastases. <i>European Journal of Surgical Oncology</i> , 2007, 33, 336-340.	1.0	13

#	ARTICLE	IF	CITATIONS
145	Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy. <i>Clinical Cancer Research</i> , 2013, 19, 5292-5299.	7.0	13
146	Systemic immune changes associated with adjuvant interferon- β -therapy in stage III melanoma patients. <i>Melanoma Research</i> , 2015, 25, 357-361.	1.2	13
147	Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. <i>Melanoma Research</i> , 2015, 25, 180-183.	1.2	13
148	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	2.8	13
149	Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials. <i>Annals of Oncology</i> , 2012, 23, ix363-ix364.	1.2	12
150	C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. <i>Melanoma Research</i> , 2021, 31, 371-377.	1.2	12
151	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	2.8	12
152	SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. <i>Annals of Oncology</i> , 2021, 32, S213-S214.	1.2	12
153	A phase II trial of sunitinib in patients with recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2008, 26, 13001-13001.	1.6	12
154	Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3521-3521.	1.6	12
155	Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. <i>Anticancer Research</i> , 2008, 28, 2459-67.	1.1	12
156	Restoration of tumor equilibrium after immunotherapy for advanced melanoma. <i>Melanoma Research</i> , 2011, 21, 152-159.	1.2	11
157	Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. <i>Melanoma Research</i> , 2015, 25, 68-74.	1.2	11
158	Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. <i>Acta Neurologica Belgica</i> , 2008, 108, 131-4.	1.1	11
159	Final Overall Results of a Study with a Novel Triplet Induction Chemotherapy Regimen (PACCAGE) Followed by Consolidation Radiotherapy in Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2009, 4, 728-735.	1.1	10
160	Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports. <i>Cancer Investigation</i> , 2012, 30, 712-720.	1.3	10
161	Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. <i>Journal of Neurology</i> , 2015, 262, 742-751.	3.6	10
162	Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma. <i>Anticancer Research</i> , 2015, 35, 5551-7.	1.1	10

#	ARTICLE	IF	CITATIONS
163	Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4865.	4.1	10
164	A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2007, 56, 247-254.	2.0	9
165	123I-2-iodo-tyrosine, a new tumour imaging agent: human biodistribution, dosimetry and initial clinical evaluation in glioma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 994-1002.	6.4	9
166	Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report. <i>BMC Ophthalmology</i> , 2021, 21, 250.	1.4	9
167	Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. <i>European Journal of Cancer</i> , 2021, 157, 225-237.	2.8	9
168	Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated with ipilimumab. <i>Journal of Clinical Oncology</i> , 2009, 27, e20006-e20006.	1.6	9
169	Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2018-2018.	1.6	9
170	A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. <i>Melanoma Research</i> , 2022, 32, 183-191.	1.2	9
171	Computer-aided detection and segmentation of malignant melanoma lesions on whole-body $\langle \text{mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si2.svg"} \rangle \langle \text{mml:msup} \rangle \langle \text{mml:mrow} / \rangle \langle \text{mml:mn} \rangle 18 \langle \text{mml:mn} \rangle \langle \text{mml:msup} \rangle \langle \text{mml:math} \rangle \text{F-FDG PET/CT}$ using an interpretable deep learning approach. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 221, 106902.	4.7	9
172	Pembrolizumab for the treatment of uveal melanoma: A case series. <i>Rare Tumors</i> , 2020, 12, 203636132097198.	0.6	8
173	Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. <i>Cancers</i> , 2021, 13, 442.	3.7	7
174	A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). <i>Cancers</i> , 2021, 13, 2010.	3.7	7
175	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021, 13, 2466.	3.7	7
176	Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitumumab (Pmab). <i>Journal of Clinical Oncology</i> , 2007, 25, 4038-4038.	1.6	7
177	A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2017-2017.	1.6	7
178	GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2034-2034.	1.6	7
179	An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals. <i>Journal of Oncology</i> , 2012, 2012, 1-8.	1.3	6
180	Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test. <i>Melanoma Research</i> , 2019, 29, 95-98.	1.2	6

#	ARTICLE	IF	CITATIONS
181	Effectiveness of dabrafenib in the treatment of patients with BRAF V600E mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	1.2	6
182	A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2534-2534.	1.6	6
183	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	3.7	6
184	CONTAMINANTS WITHIN BACTERIAL PLASMID PREPARATIONS TRIGGER APOPTOSIS IN LIPOSOME TRANSFECTED OVCAR3, BUT NOT IN SKOV3 OR AZ224 HUMAN OVARIAN CANCER CELLS. <i>Cell Biology International</i> , 2001, 25, 715-723.	3.0	5
185	9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 579.	2.2	5
186	Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases. <i>Melanoma Research</i> , 2009, 19, 385-390.	1.2	5
187	Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). <i>Annals of Oncology</i> , 2016, 27, vi386.	1.2	5
188	An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 524-527.	1.2	5
189	A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). <i>Journal of Clinical Oncology</i> , 2011, 29, 2519-2519.	1.6	5
190	Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3548-3548.	1.6	5
191	A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM). <i>Journal of Clinical Oncology</i> , 2019, 37, 9585-9585.	1.6	5
192	Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. <i>Annals of Oncology</i> , 2021, , .	1.2	5
193	Insufficient TGF-beta 1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines. <i>Anticancer Research</i> , 1999, 19, 413-20.	1.1	5
194	Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report. <i>Anticancer Research</i> , 2016, 36, 4145-9.	1.1	5
195	Anti-PD-1: When to Stop Treatment. <i>Current Oncology Reports</i> , 2022, 24, 905-915.	4.0	5
196	Vemurafenib-associated <sc>D</sc> upuytren and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1133-1135.	2.4	4
197	Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1. <i>Case Reports in Oncology</i> , 2020, 13, 1031-1036.	0.7	4
198	Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. <i>Current Oncology</i> , 2021, 28, 1630-1640.	2.2	4

#	ARTICLE	IF	CITATIONS
199	Characterization and Clinical Utility of BRAFV600 Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma. <i>Cancers</i> , 2021, 13, 3591.	3.7	4
200	Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. <i>Cancer Research</i> , 2019, 79, CT188-CT188.	0.9	4
201	Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3014-3014.	1.6	4
202	Single-center "real life experience" with pembrolizumab (PEMBRO) in pretreated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21049-e21049.	1.6	4
203	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9539-9539.	1.6	4
204	Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. <i>Frontiers in Immunology</i> , 2021, 12, 733506.	4.8	4
205	Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights. <i>Current Opinion in Oncology</i> , 2022, 34, 115-122.	2.4	4
206	Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. <i>World Neurosurgery</i> , 2009, 72, 518.	1.3	3
207	EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL). <i>European Journal of Cancer</i> , 2017, 72, S128.	2.8	3
208	A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2018, 29, x14.	1.2	3
209	Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab. <i>Annals of Oncology</i> , 2018, 29, x7.	1.2	3
210	Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy. <i>Melanoma Research</i> , 2021, 31, 272-276.	1.2	3
211	Safety of axitinib plus avelumab in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14082-e14082.	1.6	3
212	Psychosocial outcome and health-related quality of life (HRQoL) in advanced melanoma survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 162-162.	1.6	3
213	Ethical Aspects of Genetic Counseling in Familial Breast and Ovarian Cancer.. <i>Annals of the New York Academy of Sciences</i> , 1997, 833, 170-172.	3.8	2
214	Raltitrexed-related Pulmonary Toxicity. <i>Acta OncolÃ³gica</i> , 2000, 39, 537-538.	1.8	2
215	Characterization of Permanent Cell Lines That Contain the AAV2 <i>rep-cap</i> Genes on an Epstein-Barr-Virus-Based Episomal Plasmid. <i>Intervirology</i> , 2001, 44, 255-263.	2.8	2
216	Small-bowel metastasis of malignant melanoma: video capsule endoscopy appearance. <i>Endoscopy</i> , 2010, 42, E185-E185.	1.8	2

#	ARTICLE	IF	CITATIONS
217	3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. <i>European Journal of Cancer</i> , 2015, 51, S673.	2.8	2
218	A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.3	2
219	PD-L1 IHC validation and comparison of E1L3N & SP142 mAbs in melanoma. <i>Annals of Oncology</i> , 2015, 26, viii5.	1.2	2
220	COMBI-rechallenge: a phase II clinical trial on dabrafenib plus trametinib in BRAFV600-mutant melanoma patients who previously experienced progression on BRAF(+MEK)-inhibition. <i>Annals of Oncology</i> , 2016, 27, vi389.	1.2	2
221	Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006. <i>European Journal of Cancer</i> , 2017, 72, S128-S129.	2.8	2
222	Choriocapillaris Assessment In Patients Under Mek-Inhibitor Therapy For Cutaneous Melanoma: An Optical Coherence Tomography Angiography Study. <i>Seminars in Ophthalmology</i> , 2021, 36, 1-7.	1.6	2
223	A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated <i>BRAF</i> ^{V600} / <i>NRAS</i> ^{Q61R/K/L} wild-type melanoma (TraMel-WT): Interim efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9529-9529.	1.6	2
224	A Solitary Melanoma Metastasis Confined to the Submandibular Gland. <i>Case Reports in Oncology</i> , 2021, 14, 957-962.	0.7	2
225	Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma. , 2015, , .		2
226	Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium. <i>Journal of Clinical Oncology</i> , 2004, 22, 1541-1541.	1.6	2
227	PET and CT demonstration of metastatic invasion of the thoracic duct. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 392-392.	6.4	1
228	Durable Remission of Inoperable Liver Metastasis from Rectal Cancer after Hepatic Arterial Infusion of Oxaliplatin and 5-Fluorouracil in Combination with Intravenous Cetuximab. <i>Current Oncology</i> , 2011, 18, 256-259.	2.2	1
229	Loading of dendritic cells for immunotherapy. <i>ISBT Science Series</i> , 2013, 8, 161-164.	1.1	1
230	Population Pharmacokinetic Approach Applied to Positron Emission Tomography: Computed Tomography for Tumor Tissue Identification in Patients with Glioma. <i>Clinical Pharmacokinetics</i> , 2017, 56, 953-961.	3.5	1
231	Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic. <i>ESMO Open</i> , 2018, 3, e000384.	4.5	1
232	Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: A matched cohort study. <i>Annals of Oncology</i> , 2019, 30, v668-v669.	1.2	1
233	65MO A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma. <i>Annals of Oncology</i> , 2020, 31, S1443.	1.2	1
234	1131P C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. <i>Annals of Oncology</i> , 2020, 31, S759.	1.2	1

#	ARTICLE	IF	CITATIONS
235	A cohort pilot study on therapeutic vaccination of advanced melanoma patients with dendritic cells loaded with multiple peptides or electroporated with mRNA. <i>Journal of Clinical Oncology</i> , 2006, 24, 18011-18011.	1.6	1
236	Interferon alfa-2b treatment following therapeutic vaccination with mRNA electroporated dendritic cells results in skin depigmentation and tumor regression in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 8537-8537.	1.6	1
237	CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS134-TPS134.	1.6	1
238	Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2038-2038.	1.6	1
239	A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, e14012-e14012.	1.6	1
240	Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts). <i>Journal of Clinical Oncology</i> , 2007, 25, 6560-6560.	1.6	1
241	Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 9024-9024.	1.6	1
242	Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 8547-8547.	1.6	1
243	Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity. <i>Cancer Detection and Prevention</i> , 2003, 27, 380-388.	2.1	0
244	P-570 Triplet induction chemotherapy followed by radiotherapy in inoperable stage III non small cell lung cancer (NSCLC). A phase II report. <i>Lung Cancer</i> , 2005, 49, S268.	2.0	0
245	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2010, 28, e696-e697.	1.6	0
246	Reply to Prakoso et al.. <i>Endoscopy</i> , 2010, 42, 980-980.	1.8	0
247	O1.05 * AXITINIB, A SELECTIVE VEGFR-1,-2,-3 TYROSINE KINASE INHIBITOR, INHIBITS TUMOR GROWTH AND INCREASES INFILTRATION OF IMMUNE CELLS IN AN INTRACRANIAL MELANOMA MOUSE MODEL. <i>Neuro-Oncology</i> , 2014, 16, ii2-ii2.	1.2	0
248	More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs. <i>Annals of Oncology</i> , 2016, 27, vi586.	1.2	0
249	Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006. <i>Annals of Oncology</i> , 2016, 27, vi382.	1.2	0
250	Major determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey. <i>Annals of Oncology</i> , 2018, 29, viii563.	1.2	0
251	Case Report: Treatment Resistant Ipilimumab Related Colitis in an Elderly Metastatic Melanoma Patient. <i>Journal of Gerontology & Geriatric Research</i> , 2018, 07, .	0.1	0
252	A single arm, open label, phase II, multicenter study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, v544.	1.2	0

#	ARTICLE	IF	CITATIONS
253	20P Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma. <i>Annals of Oncology</i> , 2020, 31, S7.	1.2	0
254	First experience with a new implantable gold marker for extracranial high precision radiotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 5144-5144.	1.6	0
255	Proto-adjuvant chemotherapy with paclitaxel (P), carboplatin (C) and gemcitabine (G) in locally advanced inoperable non-small cell lung cancer (NSCLC). A phase II study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7285-7285.	1.6	0
256	Comparing immunogenicities of tumor-specific antigens administered as therapeutic vaccines in metastatic melanoma patients. <i>Journal of Clinical Oncology</i> , 2007, 25, 3003-3003.	1.6	0
257	The role of MGMT promotor hypermethylation as a predictive factor for response to temozolomide in recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 12509-12509.	1.6	0
258	Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).. <i>Journal of Clinical Oncology</i> , 2016, 34, e21058-e21058.	1.6	0
259	Abstract B003: A randomized controlled phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. , 2016, , .		0
260	Whole-body MRI (WB MRI) including diffusion weighted (DW) imaging for the surveillance of melanoma patients at high risk for recurrence following surgery or systemic therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21072-e21072.	1.6	0
261	Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21030-e21030.	1.6	0
262	Emotional and cognitive disturbances in long-term melanoma survivors treated with ipilimumab.. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-97.	1.6	0
263	ctDNA as a noninvasive monitoring tool in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9548-9548.	1.6	0
264	Automated threshold selection on whole-body 18F-FDG PET/CT for assessing tumor metabolic response. , 2020, , .		0
265	First experience with a new implantable gold marker for extracranial high precision radiotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 5144-5144.	1.6	0